ArticleBMC microbiology2025
Global concerns, local challenges: the alarming spread of FC428-related gonococcal strains in Nanchang City, 2021.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesAntimicrobial resistance (AMR) in N. gonorrhoeae is a major global health issue, with most ceftriaxone treatment failures linked to Asian strains, especially FC428-related strains. Since 2019, Nanchang City has participated in World Health Organization’s surveillance program, but local AMR assessments were lacking. This study aimed to examine the AMR profiles and molecular traits of N gonorrhoeae from Nanchang in 2021.
methodsWe used antibiotic susceptibility testing and whole genome sequencing for AMR surveillance, genotyping, resistance gene identification, and evolutionary analysis.
resultsIn 2021, Nanchang reported resistance rates of 68.5% for penicillin, 81.5% for tetracycline, 100% for ciprofloxacin, 5.6% for azithromycin, 0% for spectinomycin, 13% for ceftriaxone and 20.4% for cefixime. Decreased susceptibility was 16.7% for ceftriaxone. Twelve strains exhibited cephalosporins MICs ≥ 0.125 mg/L, with single-nucleotide polymorphisms in genes like porB, tbpB, penA, mtrR, ponA, gyrA and parC being key contributors to different NG-MAST and NG-STAR genotypes. For MLST, the predominant genotypes were MLST-7365 (n = 5) and MLST-8123 (n = 2), with additional genotypes including MLST-1580, MLST-1903, MLST-7367, MLST-8126, and MLST-15278. Resistance markers like penA mosaic mutations, blaTEM-1, and blaTEM-135 plasmids were detected in cephalosporins and penicillin high-level resistant strains. Among above cephalosporins decreased-susceptible isolates, six strains with penA-60.001 mosaic mutation were found to be related to global FC428-related clones previously, particularly those originating from domestic strains.
conclusionsThe study highlights high AMR rates in N. gonorrhoeae in Nanchang, China, in 2021, particularly strains with decreased cephalosporin susceptibility, threatening their effectiveness as a first-line treatment, likely due to the spread of FC428 subclones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.